PR Newswire BiotechOriginal article
Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online
Positive
AI Analysis
Summary
Vector Science & Therapeutics has commenced peptide production at LyoGenesis's first manufacturing suite, which achieved cGMP and FDA quality standards compliance. The facility will initially produce 55,000 pre-sold vials of peptides with three additional production suites scheduled to launch in September 2026.
Outcome Details
Manufacturing facility achieved cGMP, FDA, and ISO quality standards compliance; 55,000 vials of peptides in initial production run with pre-sold inventory
Importance:6/10
Sentiment:
0.60
manufacturingpeptidescGMPFDA compliancecapacity expansionLyoGenesis
Related Companies
Read the original article
Published by PR Newswire Biotech on August 24, 2026 11:30 AM